3h agoThe FlyBULLISH 63Product/PR
Why Is ORUKA THERAPEUTICS I (ORKA) Stock Moving Today?
By the Top Tier Newswire AI Desk · reviewed against 5 wire stories
ORUKA THERAPEUTICS I (ORKA) is drawing unusual attention today. Our newswire has captured 5 stories on ORKA across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for ORKA publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
ORKA by the numbers
7 sessions: +5.19%Coverage: 5 stories / 5 sourcesAI sentiment: 58/100 (bullish)
The headlines behind the move
4h agoInvestorsHubBEARISH 38Product/PR
Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data
Oruka Therapeutics shares fall 5% after the company reports Week 28 data from its Phase 2a EVERLAST-A trial of ORKA-001 in plaque psoriasis.
4h agoInvesting.com MarketsBEARISH 42Product/PR
Oruka Therapeutics stock falls despite positive trial data
Oruka Therapeutics stock falls despite positive trial data
5h agoMarketChameleonBULLISH 73Product/PR
Oruka’s ORKA-001 posts rising Week 28 skin-clearance rates with no dosing after Week 4 September 23, 2026
Oruka Therapeutics reported positive Week 28 data from its EVERLAST-A Phase 2a trial of ORKA-001 in plaque psoriasis, with PASI 100 rising to 71.4% and PASI 90 to 87.3% despite no dosing after Week 4 in the active arm. The company said safety remained consistent with the IL-23p19 class, and it expects 52-week EVERLAST-A data in December 2026 and 16-week EVERLAST-B data in 4Q 2026.
6h agoBusiness InsiderBULLISH 73Product/PR
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with...
Frequently asked questions
Why is ORKA stock moving today?
ORUKA THERAPEUTICS I (ORKA) is drawing unusual attention today. Our newswire has captured 5 stories on ORKA across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100). The most recent driver: "Oruka Therapeutics ORKA-001 data meet base case, says Clear Street" (The Fly).
Is ORKA a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ORKA coverage reads 58/100 over 5 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is ALKT down today (-19.54%)
- Why is VOYG down today (-17.32%)
- Why is RAPP down today (-16.73%)
- Why is CGEM down today (-15.37%)
- Why is INNV down today (-15.25%)
- Why is SECZ up today (+13.54%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ORKA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.